World Health Organization, UNAIDS and The University of New South Wales: Access to Care in the Context of HIV Vaccine and Other Prevention Trials - Setting Standards and Making it Happen Through Participation  SUSA6 World Health Organization, UNAIDS and The University of New South Wales
Type:	Non-commercial Satellite Back
Venue:	Parkside Ballroom B
Time:	14:45 - 16:45, Sunday, 22.07.2007
Code:	SUSA6
Click here to see a webcast of this session on kaisernetwork.org

At the end of the session, panelist and participants will be able to: 1. Refer to existing ethical guidance on access to care in the context of clinical vaccine trials and other prevention trials; 2. From the perspective of their practical application in field settings, recognize the contents and limitations of existing ethical guidance documents 3. Describe principles and proposed approaches to build on existing ethical guidance documents towards a participatory process for decision making and implementation 4. Identify opportunities to define collectively agreed standards of care, treatment and support in the context of vaccine clinical trial and prevention trials, as well as obstacles and ways to surmount them.

    Presentations in this session:

SUSA606 Powerpoint (408 KB)	A country perspective - India Vasantha Muthuswamy, India
SUSA607 Powerpoint (56 KB)	An institutional perspective on the provision of care in vaccine and prevention trials (NIH USA) Christine Grady, United States
SUSA605 Powerpoint (2.41 MB)	Bringing communities into decisions affecting their life Cheryl Overs, United Kingdom
SUSA604	Experience from the Tenefovir Trial Kathleen MacQueen, United States
SUSA602 Powerpoint (808 KB)	HIV Vaccine Development: Enabling the efforts through policy development Saladin Osmanov, Switzerland
SUSA601	Introduction to the session TBD TBD, Germany
SUSA603	Prevention trials: setting standards of access to prevention Catherine Hankins, Switzerland
SUSA608 Powerpoint (108 KB)	Setting standards for access to care, treatment and support in vaccine trials: a proposed participatory process Daniel Tarantola, Australia

Format: The Session will be run as a series of short presentations with interventions from presenters and from the during the general discussion half-way and at the end of the session. Participants: Participants to this open session will include: scientists engaged in vaccine and prevention trials; clinicians and other health services professionals; social scientists; members of communities likely to participate in clinical trials; community-based workers; ethicists; staff of funding agencies, public and private research and development groups, research sponsoring organizations; academics and students. The number of participants will be in the order of 100. Presenters: The panel will include presenters as listed in the table, below. Working titles are listed for each presentation, to be modified upon consultation between sponsoring agencies and presenters. Structure of the session: The session will run continuously for 120 minutes. A Chair will introduce the objectives of the session and the presenters, facilitate the debate and present a short summary at the end of the session. Each presenter will speak for no more than 10 minutes, leaving 15 minutes half-way and at the end of the session for general discussion. Introduction and Wrap-up by the Chair will take 5 minutes each. Each presenter will be allowed up to 8 PowerPoint slides. This material will be made available to participants as printed hand-outs at the end of the session and/or displayed on the Conference website or through other media as provided for by Conference Organizers. Additional printed materials may be made available for distribution or display at the request of presenters. Contact person in Sydney: Prof Daniel Tarantola The University of New South Wales Faculty of Medicine School of Public Health and Community Medicine Samuels Building, Level 2, Room 228 UNSW Sydney 2052 Australia d.tarantola@unsw.edu.au Tel +61 2 9385 8268 Fax +61 2 9385 1036